Soriot sharpens broom in AstraZeneca C-suite sweep
This article was originally published in Scrip
Executive Summary
AstraZeneca's new CEO Pascal Soriot has wasted little time in putting his stamp on the troubled company, eliminating R&D chief Martin Mackay and global commercial head Tony Zook in a management shake up.
You may also be interested in...
AstraZeneca Groomed Paul Hudson For His New Role … At Novartis
Ten years at AstraZeneca PLC have prepared US President and Executive Vice President of North America Paul Hudson for his next C-suite job, but unfortunately for his current employer that gig is with a major competitor – Novartis AG.
10 Approvals To Look Out For In Q3 2023
The third quarter could bring US approvals for a range of novel drugs, including the first treatment for a common eye disease, the first US approval of PD-1/L1 inhibitor from a Chinese firm, and the first oral therapy for postpartum depression.
ADAURA Survival Boost For AZ’s Tagrisso
Impressive overall survival data from the Phase III ADAURA trial should boost both EGFR testing in non-small cell lung cancer, and sales of the blockbuster NSCLC therapy.